(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 22 July 2004 (22.07.2004)

PCT

(10) International Publication Number WO 2004/060403 A3

(51) International Patent Classification⁷: A61P 25/00

A61K 47/48,

(21) International Application Number:

PCT/CA2004/000011

(22) International Filing Date: 5 January 2004 (05.01.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/437,986

6 January 2003 (06.01.2003) U

- (71) Applicant (for all designated States except US): TRANS-FERT PLUS [CA/CA]; 550 Sherbrooke West, Suite 100, H3A 1B9 Montréal, Québec (CA).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BÉLIVEAU, Richard [CA/CA]; 266 Wilson, H3E 1L8 Montréal, Québec, CA (CA). DEMEULE, Michel [CA/CA]; 3557 Archambault, J4M 2W8 Longueuil, Québec, CA (CA).


- (74) Agent: OGILVY RENAULT; Suite 1600, 1981 McGill College Avenue, H3A 2Y3 Montréal, Québec, CA (CA).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

[Continued on next page]

(54) Title: APROTININ AND ANGLOS AS CARRIERS ACROSS THE BLOOD-BRAIN BARRIER



(57) Abstract: The present invention relates to improvements in the field of drug delivery. More particularly, the invention relates to a non-invasive and flexible method and carrier for transporting a compound or drug across the blood-brain barrier of an individual. In particular the present invention relates to a carrier for transporting an agent attached thereto across a blood-brain barrier, wherein the carrier is able to cross the blood-brain barrier after attachment to the agent and thereby transport the agent across the blood-brain barrier. The present invention relates to improvements in the field of drug delivery. More particularly, the invention relates to a non-invasive and flexible method and carrier for transporting a compound or drug across the blood-brain barrier of an individual. In particular the present invention relates to a carrier for transporting an agent attached thereto across a blood-brain barrier, wherein the carrier is able to cross the blood-brain barrier after attachment to the agent and thereby transport the agent across the blood-brain barrier.

~

ï.

INTERNATIONAL SEARCH REPORT

International Application No PCT/CA2004/000011

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K47/48 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) I PC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	DE 199 53 696 A (CHERKASKY ALEXANDER) 10 May 2001 (2001-05-10)	1-4, 7-21, 24-38, 41-53, 56-67, 70-78, 80-102		
	column 1, lines 15-32; claim 3; figure 1	00 102		
	-/			
, [•			
		·		

X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	"X" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
19 May 2004	3 0. 09. 2004
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Gonzalez Ramon, N

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA2004/000011

A 44		PCT/CA2004/000011	
C.(Continua Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
A	WO 02/33090 A (PROCYON BIOPHARMA INC) 25 April 2002 (2002-04-25)	1-5, 7-22, 24-39, 41-54, 56-68, 70-78, 80-102	
	page 1, lines 42,43; claims 12,22,36,46,52,58,75,82,88; example 18		
Ą	GUILLOT F L ET AL: "ANGIOTENSIN PEPTIDE REGULATION OF BOVINE BRAIN MICROVESSEL ENDOTHELIAL CELL MONOLAYER PERMEABILITY" JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, NEW YORK, NY, US, vol. 18, no. 2, 1991, pages 212-218, XP008030278 ISSN: 0160-2446 abstract page 217, column 2	1-5, 7-22, 24-39, 41-54, 56-68, 70-78, 80-102	
γ	KOBAYASHI H ET AL: "THE PROTEASE INHIBITOR BIKUNIN, A NOVEL ANTI-METASTATIC AGENT" BIOLOGICAL CHEMISTRY, XX, XX, vol. 384, no. 5, 1 May 2003 (2003-05-01), pages 749-754, XP008030275 ISSN: 1431-6730 abstract; figure 2	1-5, 7-22, 24-39, 41-54, 56-68, 70-78, 80-102	
		•	

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

3

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 5, 22, 39, 54, 68 complete; 1-4, 7-21, 24-38, 41-53, 56-67, 70-78, 80-102 partially

Carrier for transporting an agent atached thereto across the blood brain barrier wherein the agent is anticancer agent paclitaxel. Conjugate comprising the carrier and paclitaxel, pharmaceutical composition and use of the same for neurological disease (brain tumour, brain metastasis, schizophrenia, epilepsy, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke and obesity).

2. claims: 1-4, 6-21, 23-38, 40-53, 55-67, 69-79, 80-102 partially

Carrier for transporting an agent atached thereto across the blood brain barrier wherein the agent is a green fluorescent protein, a histag protein, and beta galactosidase. Conjugate comprising the carrier and the protein agent, pharmaceutical composition and use of the same for neurological disease (brain tumour, brain metastasis, schizophrenia, epilepsy, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke and obesity)

3. claims: 1-4, 6-21, 23-38, 40-53, 55-67, 69-79, 80-102 partially

Carrier for transporting an agent atached thereto across the blood brain barrier wherein the agent is a green fluorescent protein, a histag protein, and beta galactosidase. Conjugate comprising the carrier and the protein agent, pharmaceutical composition and use of the same for neurological disease (brain tumour, brain metastasis, schizophrenia, epilepsy, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke and obesity)